Clinical Trial Update: Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating ribociclib with letrozole in locally advanced, ER-positive, HER2-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Luminal Breast Cancer

Drugs mentioned

• FEMARA (letrozole)
• KISQALI (ribociclib)

Snippet

Sponsor: University Hospital, Akershus | Conditions: Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Status: COMPLETED